Symphogen A/S is a biotechnology company based in Lyngby, Denmark, specializing in the development of therapeutic antibodies. The organization focuses on creating innovative solutions for the treatment of various diseases, leveraging its proprietary Symphogen technology platform. This platform enables the generation of complex antibody mixtures, which can enhance therapeutic efficacy and safety. Symphogen is dedicated to advancing the field of biopharmaceuticals through rigorous research and development in the antibody space.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

24 Patents

#5 in Lyngby

#121 in Denmark

#26,686 in the World

Lyngby, Denmark

Symphogen A/s

Forward Citations = 339

53 inventors:

Mikkel Wandahl Pedersen (13 out of 18 patents)

Klaus Koefoed (9 out of 15 patents)

Michael Kragh (9 out of 14 patents)

4. Johan Lantto (7 out of 9 patents)

5. Helle Jane Jacobsen (7 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Symphogen A/s. Retrieved from https://idiyas.com/company/symphogen-a-s

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

4 patents (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

14 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]